Edition:
United States

Accelerate Diagnostics Inc (AXDX.O)

AXDX.O on Consolidated Issue listed on NASDAQ Capital Market

21.70USD
18 Aug 2017
Change (% chg)

$-1.85 (-7.86%)
Prev Close
$23.55
Open
$24.50
Day's High
$24.97
Day's Low
$21.65
Volume
1,225,291
Avg. Vol
341,387
52-wk High
$30.45
52-wk Low
$19.20

AXDX.O

Chart for AXDX.O

About

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic... (more)

Overall

Beta: 2.05
Market Cap(Mil.): $1,302.27
Shares Outstanding(Mil.): 55.30
Dividend: --
Yield (%): --

Financials

  AXDX.O Industry Sector
P/E (TTM): -- 118.24 32.70
EPS (TTM): -1.23 -- --
ROI: -51.67 9.40 14.88
ROE: -51.88 14.58 16.12

BRIEF-Accelerate Diagnostics reports Q2 loss per share $0.31

* Accelerate Diagnostics reports Q2 2017 financial results, doubles revenue generating placements

Aug 03 2017

BRIEF-Accelerate Diagnostics announces closing of $79.3 mln upsized offering

* Accelerate Diagnostics announces closing of $79.3 million upsized offering Source text for Eikon: Further company coverage:

May 15 2017

BRIEF-Accelerate Diagnostics prices upsized offering of 2.75 mln shares at $28.85 per share

* Accelerate diagnostics announces pricing of upsized public offering of common stock

May 09 2017

BRIEF-Accelerate Diagnostics reports Q1 sales $530,000

* Accelerate Diagnostics reports 191 instruments under contract and 3x revenue growth for first quarter 2017

May 03 2017

BRIEF-Accelerate Diagnostics reports Q1 sales $530,000

* Accelerate Diagnostics reports 191 instruments under contract and 3X revenue growth for first quarter 2017

May 03 2017

BRIEF-Accelerate Diagnostics names Tom Brown to board of directors

* Accelerate Diagnostics names Tom Brown to board of directors

Mar 15 2017

Earnings vs. Estimates